Kornimate/medical-research-clean huggingface dataset:
nutfish and nutrient supplementation in pregnancy class to improve maternal and birth outcomes

Conditions: Pregnancy; Protein-Energy Malnutrition; Anemia

Summary: this study evaluates the intervention of nut fish based food, micro nutrients supplementation and pregnancy class to improve maternal and birth outcome. this is cluster randomized trial with two arms. the intervention group will receive nut fish based supplementation, multiple micro nutrients, and pregnancy class. the control group will receive government food supplementation, iron folic acid supplementation, and pregnancy class.

objectives: to investigate whether a nut fish based food and dietary supplementation delivered to pregnant mothers with health education would benefit maternal and birth outcomes compared with the government standard of care. design. a randomized control trial will be implemented in rural community in indonesia. intervention. the 2 trial arms will be control group (government standard of care) and intervention group with nut fish based food and dietary supplementation and health education series in the pregnancy class. a control group will receive government food supplementation package, iron folic acid pills and pregnancy class. an intervention group will receive nutfish based food supplementation, multiple micro nutrients, and pregnancy class. as a pilot study, all the intervention packages will be delivered by research team members. subjects. a total 72 first trimester of pregnant mothers will be enrolled with 36 pregnant mothers each group. outcome measures. maternal outcome at 1 and 2 month after intervention namely weight increment, energy and protein intake, mid upper arm circumference, and complications. birth outcomes include apgar score, birth weight and length, preterm birth. analysis. linear, logistic and multinomial logistic regression.

Eligibility criteria:
inclusion criteria: * first trimester of pregnancy * anemic or mid upper arm circumference \< 23.5cm or no weight gain * plan to deliver at village midwives * residence in the study area exclusion criteria: * severe anemia \< 7.0g/dl
joining under-connected networks to optimize "salud" (health) ("juntos")

Conditions: Hiv

Summary: the objective of this study is to evaluate the juntos referral network as an implementation strategy to enhance the reach of hiv-prevention and treatment services to latino gay, bisexual, and other men who have sex with men (msm).


Eligibility criteria:
inclusion criteria: hiv test counselors: * 18 years of age or older * certified as an hiv test counselor in miami-dade county or broward county (at the time of enrollment) * working or volunteering as an hiv test counselor in miami-dade county or broward county and report testing 1 or more latino msm client per week (at the time of enrollment) * plans to continue working or volunteering as an hiv test counselor in miami-dade county or broward county for the next 6 months * reports suboptimal fidelity to pre-exposure prophylaxis (prep) referral guidelines (\<90% fidelity) and/or self-reports an unmet need for hiv prevention/treatment referral resources * willing and able to recruit 4-5 latino msm testing clients into the study latino msm: * 18 years of age or older * identifies as latino/a/x or hispanic * identifies as a sexual minority man or reports being a man who has sex with men * speaks english and/or spanish * received an hiv test from an hiv test counselor participating in the study * lives in miami-dade county, broward county, or palm beach county and anticipates living there for the next three months exclusion criteria: hiv test counselors: * unable to consent * study personnel unable to verify hiv test counselor role in miami-dade county or broward county (e.g., confirmation of where they work/volunteer as hiv test counselor, location they state they provide services doesn't exist or does not provide hiv testing services) * works as an hiv test counselor in an incarceration/prison setting (i.e., clients are prisoners) latino msm: * unable to consent
affective processing in depression and epilepsy

Conditions: Epilepsy; Depression; Healthy

Summary: the goal of this study is to determine whether there are unique markers on neuroimaging that are associated with depression in epilepsy.

symptoms of depression is commonly seen in patients with epilepsy. there are similarities and differences between depressive symptoms in epilepsy when compared with primary depression. through the use of fmri (functional mri), we hope to determine whether there are unique markers on neuroimaging that are associated with depression in epilepsy.

Eligibility criteria:
for control group inclusion criteria: * healthy adults of 18 years of age or older. exclusion criteria: * subject has no history of affective disorders * subject scores higher than 5 on hamilton depression rating scale * subject with prior primary diagnosis of any psychotic disorder, bipolar disorder, anxiety disorder, or any other serious medical or neurological disorder * subject is pregnant * subject is unable to undergo a mri epilepsy only group inclusion criteria: * subject is at least 18 years of age * subject has confirmed temporal lobe epilepsy (tle) exclusion criteria: * subject has a history of depression * subject scores higher then 5 on hamilton depression rating scale * subject with prior primary diagnosis of any psychotic disorder, bipolar disorder, anxiety disorder, or any other serious medical or neurological disorder * subject is pregnant * subject is unable to undergo a mri depression only group inclusion criteria: * subject is at least 18 years of age * subject scores between 12 and 18 on hamilton depression rating scale exclusion criteria: * subject scores higher than 18 on hamilton depression rating scale * subject is currently being medicated for depression * subject has history of major depression or dysthymia * subject with prior primary diagnosis of any psychotic disorder, bipolar disorder, anxiety disorder, or any other serious medical or neurological disorder * subject is pregnant * subject is unable to undergo a mri depression and epilepsy group inclusion criteria: * subject has confirmed temporal lobe epilepsy (tle) * subject scores between 12 and 18 on hamilton depression rating scale exclusion criteria: * subject has history of major depression or dysthymia * subject is currently on medication for depression * subject with prior primary diagnosis of any psychotic disorder, bipolar disorder, anxiety disorder, or any other serious medical or neurological disorder * subject is pregnant * subject is unable to undergo a mri

Keywords: epilepsy depression neurology fmri healthy controls
evaluation of an ultraportable ecg recording device and its visualization software for the detection of atrial fibrillation

Conditions: Cardiovascular Illnesses

Summary: the purpose is to demonstrate the usefulness of witcard and witdisplayer in the diagnosis of af but more generally in the qualification of the heart rhythm and the diagnosis of cardiac arrhythmias. the main objective is therefore to demonstrate that at least 90 +/- 0.03% of ecgws are interpretable by a physician and the primary endpoint will therefore be the ratio of the number of ecgws that allowed a physician to make a diagnosis. rhythmic (ecgw interpretable) and the total number of ecgw recorded and viewed. the clinical trial as part of the ce medical device certification process for secondary objectives and ancillary studies will be required to assess the diagnostic performance of the witcard + witdisplayer system, the quality of the ecgw recorded by the witcard, the the safety of using the witcard, the technical performance of the witcard ecg recorder, the ergonomics of the witcard, and finally the performance of automatic cardiac rhythm classification algorithms.

monocentric, prospective, interventional study

Eligibility criteria:
inclusion criteria: patient, male or female, over 18 years of age, presenting to the cardiology-rhythmology department (consultations and hospitalizations) or to the emergency department of the timone 2 hospital for the management of suspicion of disorder heart rate in front of: * palpitations * dyspnoea, acute pulmonary edema, non-ischemic heart failure * malaise, lipothymia, syncope exclusion criteria: * patients with clinical criteria that do not warrant the use of witcard: * immediate vital risk whatever its nature * rhythmic urgency requiring treatment without delay: respiratory, circulatory or neurological distress * acute coronary syndrome * pregnant women * non-beneficiaries of a social security scheme * persons deprived of their liberty * patient participating in another study * patient in a period of exclusion determined by a previous study * patient under the protection of justice, under guardianship or under guardianship
effects of clobazam on sleep and daytime function in patients with epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to monitor the effect of clobazam on sleep and daytime alertness in people with epilepsy.

many studies show that patients with epilepsy frequently have disrupted sleep, as well as a high level of daytime sleepiness. this may be due to a sleep disorder, nighttime seizures that lead to disrupted sleep, and other abnormalities. sleep complaints are widely reported among patients with various epilepsy syndromes. anti-seizure treatments may affect sleep. effects vary by type of medication and other health issues. generally, with improvement of seizure control, the sleep cycle improves and becomes more regular. however, some anti-seizure medications have been associated with insomnia. there have been studies that looked at sleep in relation to some anti-seizure medications. however, there are no currently available published reports on the effect of clobazam (onfi) on sleep.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older * diagnosis of epilepsy who are being considered for treatment with clobazam exclusion criteria: * known untreated moderate or severe sleep apnea * major circadian rhythm disorders

Keywords: epilepsy sleep antiepileptic drugs
toward elimination of hepatitis c virus (hcv): a pilot study

Conditions: Hepatitis C; Addict Heroin

Summary: to demonstrate that colocation treatment of substance use disorder and hepatitis c infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of hepatitis c virus in study participants.

to demonstrate that colocation treatment of substance use disorder and hepatitis c infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of hepatitis c virus in study participants. primary objective: 1. cure rates (svr-12, hcv plasma rna not quantifiable 12 weeks after last dose of treatment) of hcv in 30 recently identified pwids under 30 years old secondary objectives: 1. rate of sobriety maintenance for 1 year after enrollment 2. re-infection rate with hcv over 1 year after enrollment 3. re-admission rates for detox 4. cravings

Eligibility criteria:
inclusion criteria: * age 18 - 30 * successfully detoxed at phbh from opioids * agree to participate in a closely monitored program * positive hcv vl \> 5,000 on two tests * minimum one follow-up visit after discharge from phbh to be enrolled * any genotype * apri less than 1 and fibrosure less than 0.45 * negative pregnancy test in women and females must agree to acceptable contraception during treatment of hcv. oral contraceptives that do not contain ethinyl estradiol are allowed with mavyret * treatment naïve for hcv * signed informed consent exclusion criteria: * cirrhosis * co-infection with hiv or hbv * inability to comply with treatment or follow up * renal failure with gfr less than 50 ml/min5\* * any prior treatment for hcv * diabetes with hga1c more than 8.0 * clinically significant abnormalities, other than hcv infection, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ecg) that make the subject an unsuitable candidate for this study in the opinion of the investigator, including, but not limited to: * alt/ast \> 10x normal value, * wbc with anc \< 1500 cell/ul, * hemoglobin \< lln, * treatment for cancer or lymphoma in the past 5 years, * hemoglobin a 1c \> 8%. * any uncontrolled psychiatric, cardiac, respiratory, gastrointestinal, hematologic, neurologic, psychiatric, or other medical disease or disorder, which is unrelated to the existing hcv infection which in the opinion of the pi would prevent adherence to and participation in the trial. * hypersensitivity to naltrexone or polylactide-co-glycolide (plg) microspheres
non-severe traumatic injuries evaluation using smartphone camera for extra-hospital regulation

Conditions: Mild Traumatic Injury; Pre-hospital Dispatching; Visioconference

Summary: photography teletransmission allow a better and optimized dispatching of patients calling an emergency medical call center (emcc) for a mild traumatic injury. it has previously been studied for patients to whom an ambulance was sent and therefore presumed to be older or with co-morbidities. the present trial aim to evaluate in the general population, the effect of a smartphone-mediated visioconference in the dispatching of patients calling an emcc for mild traumatic injury.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years of age), * free of will (not under any guardianship or liberty privation), * suffering from mild traumatic injury, * availability of a smartphone with internet connection for the patients or witness, * consenting to participate in the study exclusion criteria: * severe trauma requiring immediate medical assistance * trauma associated with head injury, on antiplatelet therapy (apt) or anti-coagulation therapy (act)
neuromuscular electrical stimulation in foot and ankle surgery

Conditions: Ankle Fractures

Summary: this is a pilot randomized controlled trial, wherein the intervention group will undergo nmes five days a week beginning three weeks postoperative and lasting for ten weeks. both the control and intervention groups will start standard physical therapy six weeks postoperative. primary outcome measure will be the isometric strength of the gastrocnemius muscle. the secondary outcomes will comprise subjective clinical evaluations (using the lower extremity functional scale \[lefs\]), functional assessments such as the sit-to-stand test, 2-minute walk test, stair climb test and objective clinical evaluation using contralateral comparison of calf circumference.


Eligibility criteria:
inclusion criteria: * capable and willing to provide informed consent * undergoing a procedure that involves repairing an ankle fracture. exclusion criteria: patients with medical histories that include: * rheumatoid arthritis * connective tissue disorders * chronic corticosteroid use * implanted electrical devices * neurological disorders * non-ambulatory status * recent surgery (within the last 3 months) that is not related to the study * scheduled to undergo surgery in the near future * epilepsy * diagnosed with cancer * have suffered acute trauma or recently have had a surgical procedure (not related to the study) * have cardiac problems or cardiac disease * have an abdominal hernia * have venous thrombosis
glargine dosing in hospitalized patients with type 2 diabetes and renal insufficiency

Conditions: Type 2 Diabetes; Renal Insufficiency

Summary: it is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. this will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated gfr by mdrd as follows: \< 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.

this study will enroll 180 hospitalized patients with type 2 diabetes and moderate to end stage renal insufficiency (estimated glomerular filtration rate is \< 30 ml/min/1.73m2 or dialysis) in the chicagoland area. participants will be randomized into 1 of 2 protocols after hospital admission. blood glucose levels will be obtained before meals, at bedtime and whenever necessary for any signs or symptoms of hypoglycemia. the primary endpoint will be the percentage of blood glucose levels reaching goal of 80-180mg/dl. a secondary endpoint will be the percentage of hypoglycemic events, defined as blood glucose values \< 60 mg/dl. in addition the percentage of glucose levels within the goal range of 80-180mg.dl will be further separated into excellent control (80-140mg/dl) and acceptable control (141-180mg/dl). the 2 study groups will be: 1. glargine \& glulisine. the total daily insulin dose will be 0.6 units/kg. half of this will be given as glargine once daily. the other half will be given as glulisine, divided equally between breakfast, lunch, and dinner with correction factor dosing as needed for elevated premeal hyperglycemia. 2. glargine \& glulisine the calculation for the total daily insulin dose will be 0.3 units/kg. half of this will be given as glargine in the morning. the other half will be given as glulisine, divided equally between breakfast, lunch, and dinner, with correction factor dosing as needed for elevated premeal hyperglycemia. all oral agents will be discontinued on admission.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus of mor than 1year * gfr less than 30 ml/min/1.73m2 or dialysis * age greater than 18years * entry blood glucose (fasting or random) greater than 180mg% exclusion criteria: * type 1 diabetes mellitus * new onset hyperglycemia * pregnant * solid organ transplant within 1 year * steroids prednisone greater than 7.5mg/day or equivalent * hospital los predicted less than 2 days * severe liver disease * known hypopituitarism or adrenal insufficiency * patients in the icu * patients with hypoglycemic unawareness * outpatient insulin dose less than 0.6 units/kg

Keywords: glargine glulisine type 2 diabetes renal insufficiency
efficacy and safety of abelmoschus manihot for iga nephropathy

Conditions: IgA Nephropathy

Summary: -iga nephropathy is the most common primary glomerular disease in china, huangkui capsule is a single medicament of traditional chinese medicine consists of abelmoschus manihot and has been widely used to treat kidney disease. the purpose of this study is to evaluate the safety and efficacy of abelmoschus manihot for treating iga nephropathy in large scale samples with long time take.

the test has not been completed .

Eligibility criteria:
inclusion criteria: * clinical diagnosed as chronic nephritic syndrome * iga nephropathy diagnosed by kidney biopsy * aged from 18 to 65 years，male or female * blood pressure of ≤140/90mmhg * estimated glomerular filtration rate (egfr)≥45ml/min/1.73 m2 * 24-hour proteinuria ranged between 0.5g-3.0g * obtaining the signed informed consent from patients exclusion criteria: * secondary iga nephropathy * be allergic to huangkui capsule or losartan potassium tablet * taken huangkui capsule or acei or arb in last 6 weeks * taken the glucocorticoids, immunosuppressants or common threewingnut root and such as drugs with immunosuppressive actions in the last 12 months * blood pressure \<90/60mmhg * serum potassium level \> 5.5mmol / l * serum albumin level \<30g / l * lactation, pregnancy or plans pregnancy during the study period * unilateral or bilateral renal artery stenosis * combined with severe primary diseases of heart, brain, liver and hematopoietic system and so on, or other serious diseases which can affect the patient's life * participating in another clinical study in the same period

Keywords: abelmoschus manihot iga nephropathy proteinuria efficacy safety
mutational analysis as a prognostic and predictive marker of cardiovascular (cvd) disease in patients with myelodysplasia

Conditions: MDS; Cardiovascular Diseases; Inflammation

Summary: this study evaluates the relationship between myelodysplastic syndromes (mds) and cardiovascular disease. mds patients will be evaluated for the presence of mutations and whether they are associated with an increased risk of heart disease (cvd) and inflammation compared to healthy adults. patients without symptoms of cvd will receive ct scans to assess for hidden disease and if that is related to their mutations.

myelodysplastic syndromes (mds) are a type of blood cancer that can cause infection or bleeding because they prevent the formation of blood components and may lead to leukemia and death. mds can arise from changes (or mutations) to a patient's dna. mds patients have increased risk of heart disease compared to healthy adults. the investigators will look for links between mutations in mds patients and increased risk of heart disease. they will also use "ct imaging" to see if mds patients have asymptomatic artery disease but may lead to heart disease in the future and if that is related to their mutations. the researcher will try to link mutations in mds patients to markers of inflammation and to the amount of artery disease on ct imaging to look for patterns. the goal is to find certain mutations that are associated with inflammation and heart disease. this may ultimately allow hematologists to test mds patients with these mutations for heart disease and/or treat them early so they have a better and longer life.

Eligibility criteria:
inclusion criteria: * diagnosis of: myelodysplastic syndrome (mds), myeloproliferative neoplasm (mpn), chronic myelomonocytic leukemia leukemia (cmml), or low-blast acute myeloid leukemia (aml, blasts 20-29%) less than 24 months ago * alive and registered in the mds-canada (mds-can) database * known comorbidity history and known history of cardiovascular disease * able to provide peripheral blood sample for cytokine analysis * able top provide samples for next generation sequencing (ngs) - if diagnosis 0-6 months ago: peripheral blood; if diagnosis 6-24 months ago: diagnostic bone marrow aspirate slides or peripheral blood exclusion criteria: * mds/mpn patients other than cmml due to higher prevalence of janus kinase 2 (jak2) mutation (a known risk factor for cvd) * disease progression without available diagnostic bone marrow slides for ngs

Keywords: ct imaging next generation sequencing myelodysplastic syndrome